{
    "clinical_study": {
        "@rank": "125970", 
        "acronym": "PRISMA-1", 
        "arm_group": [
            {
                "arm_group_label": "Risperidone ISM 50mg", 
                "arm_group_type": "Other", 
                "description": "Three different single doses will be evaluated"
            }, 
            {
                "arm_group_label": "Risperidone ISM 75mg", 
                "arm_group_type": "Other", 
                "description": "Three different single doses will be evaluated"
            }, 
            {
                "arm_group_label": "Risperidone ISM 100mg", 
                "arm_group_type": "Other", 
                "description": "Three different single doses will be evaluated"
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical trial is designed to evaluate different dosages of risperidone ISM, a new\n      long-acting injectable form."
        }, 
        "brief_title": "Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM\u00ae at Different Dose Strengths", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Schizophrenia", 
            "Schizoaffective Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Psychotic Disorders", 
                "Schizophrenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This clinical trial will try to characterize and document the pharmacokinetics of\n      risperidone ISM in schizophrenic or schizoaffective patients after one intramuscular\n      injection at different dose strengths.Likewise, the safety and tolerability of risperidone\n      ISM will be evaluated in the above mentioned population.\n\n      Following confirmation of eligibility and a washout period for study-prohibited drugs, a\n      total of 33 subjects will be randomized in a 1:1:1 ratio to receive a single intramuscular\n      (IM) injection of one of the following dosages of study drug:\n\n      Group 1: 50 mg risperidone ISM Group 2:  75 mg risperidone ISM Group 3: 100 mg risperidone\n      ISM Several blood samples for plasma pharmacokinetic (PK) assessments will be obtained\n      pre-dose and post-dose. Safety assessments will be conducted at each pre-specified time\n      points."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Capable of providing informed consent.\n\n          -  Male or female aged \u2265 18 years to < 65 years\n\n          -  Current diagnosis of schizophrenia or schizoaffective disorder, according to the\n             Structured Clinical Interview for Diagnostic and Statistical Manual of Mental\n             Disorders Clinical Trials (SCID-CT) or the DSM-IV-TR\n\n          -  Medically stable over the last month, and psychiatrically stable without significant\n             symptom exacerbation over the last three months based on the investigator's judgment\n\n          -  Score of \u2264 4 (moderately ill) on the Clinical Global Impression - Severity of Illness\n             (CGI-S)\n\n          -  If a sexually active female of childbearing potential, using a medically accepted\n             contraceptive method.\n\n        Exclusion Criteria:\n\n          -  Presence of an uncontrolled, unstable, clinically significant medical condition that\n             in the opinion of the investigator may interfere with the interpretation of safety\n             and PK evaluations\n\n          -  If female, a positive serum pregnancy test, or planning to become pregnant between\n             now and one month after the last dose of trial medication, or currently breastfeeding\n             a child\n\n          -  History of neuroleptic malignant syndrome and current or past history of tardive\n             dyskinesia\n\n          -  Positive urine drug/alcohol screen finding, unless the positive finding can be\n             accounted for by documented prescription use.\n\n          -  In the investigator's opinion, at imminent risk of committing self-harm\n\n          -  Use of depot antipsychotics within the last three months\n\n          -  Receipt of any investigational drugs within the last three months\n\n          -  Current participation in any other clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01788774", 
            "org_study_id": "ROV-RISP-2011-01", 
            "secondary_id": "2012-003303-35"
        }, 
        "intervention": [
            {
                "arm_group_label": "Risperidone ISM 50mg", 
                "intervention_name": "Risperidone ISM 50 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Risperidone ISM 75mg", 
                "intervention_name": "Risperidone ISM 75 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Risperidone ISM 100mg", 
                "intervention_name": "Risperidone ISM 100 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Risperidone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pharmacokinetics", 
            "Safety", 
            "Risperidone ISM\u00ae", 
            "Intramuscular", 
            "Schizophrenia"
        ], 
        "lastchanged_date": "January 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "TBD", 
                        "country": "Croatia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "TBD", 
                        "country": "Russian Federation"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "TBD", 
                        "country": "South Africa"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "TBD", 
                        "country": "Spain"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Croatia", 
                "Russian Federation", 
                "South Africa", 
                "Spain"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM\u00ae at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Croatia: Agency for Medicinal Product and Medical Devices", 
                "Russia: Pharmacological Committee, Ministry of Health", 
                "South Africa: Medicines Control Council", 
                "Spain: Spanish Agency of Medicines"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the curve", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose and 18 time points Post-dose will be carried out within a 75 day time frame"
        }, 
        "removed_countries": {
            "country": "Latvia"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01788774"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Rovi Pharmaceuticals Laboratories", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rovi Pharmaceuticals Laboratories", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}